Yıl: 2022 Cilt: 29 Sayı: 9 Sayfa Aralığı: 940 - 943 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2022.02.047 İndeks Tarihi: 11-10-2022

Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis

Öz:
Aim: In this study, patients who underwent salvage Radiotherapy (RT) after biochemical recurrence (BCR) were evaluated retrospectively. The aim of this study was to evaluate the factors affecting the time to biochemical recurrence and salvage RT after radical prostatectomy. Materials and Methods: In Ankara Atatürk Education Hospital, patients with prostate cancer who received salvage RT between 01.01.2011 and 01.01.2018 were analyzed retrospectively. Patients who had undergone radical prostatectomy for prostate adenocarcinoma, and received salvage RT for PSA (Prostate-specific antigen) recurrence, were included. Patients who received post-surgery hormone therapy, and received definitive or palliative RT, were excluded. SPSS Ver. 22 software package was used for statistical analysis and the statistical significance limit was accepted as p≤0.05. Results: Results of 84 patients who met the criteria of the study were analyzed. The median follow-up was 78.5 (range 28-172) months and the median time between surgery and RT was 23.7 (range 5.1-136.9) months. The relationship between the time from surgery to BCR and the Gleason Score (GS) was statistically significant; the median time was 16.3 (2.17-125.9) months in the group with GS ≤8, and 8.9 (2.8-20.3) months in the group with GS 9-10 (p=0.05). The relationship between the time from surgery to BCR and Tumor (T) stage was statistically significant. In subgroup analysis, this difference was seen between T3A and T3B stages. That time was 17.8 (range 2.17-73.77) months in T3A and 8.7 (range 2.8-29.6) months in T3B stages (p=0.02). The relationship between the level of nadir PSA and the median time between surgery and BCR was significant. It was median 20.6 (range 5.4-65.2) months in patients with PSA< 0.03 and 8.8 (range 2.2-125.9) months in patients with PSA ≥0.03 (p<0.0001). Conclusion: BCR time is shorter in patients with high GS, advanced T stage, and high postoperative PSA nadir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 ;71:209- 49.
  • 2. Incrocci L. Radiotherapy for prostate cancer and sexual health. Transl Androl Urol. 2015;4:124-30.
  • 3. De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis. 2012 ;15:120-7.
  • 4. Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma, Cancer, 2000;89:1792–9.
  • 5. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715-7. Erratum in: J Natl Cancer Inst. 2012;104:423.
  • 6. Westesson KE, Stephenson AJ. Salvage Therapy for Prostate Cancer, Oncology & Hematology Review, 2013;9(1):21–5.
  • 7. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66:243–50.
  • 8. Toussi A, Stewart-Merrill SB, Boorjian SA, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol. 2016;195:1754-9.
  • 9. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubicprostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001 Aug;28(3):555-65.
  • 10. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003 Feb;169(2):517-23.
  • 11. Kasibhatla M, Peterson B, Anscher MS. What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? Prostate Cancer Prostatic Dis. 2005;8(2):167.
  • 12. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15- year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185:869-75.
  • 13. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-12.
  • 14. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117:5039-46.
  • 15. Patel AR, Stephenson AJ. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol. 2011 Jun 14;8(7):385-92.
  • 16. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1;117(13):2883-91.
  • 17. Freedland SJ, Rumble RB, Finelli A, et al. Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2014 Nov 3. pii: JCO.2014.58.8525.
  • 18. Freedland SJ, Aronson WJ, Presti JC Jr, et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004;100:1633-8.
  • 19. Salomon L, Anastasiadis AG, Johnson CW, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology. 2003;62:304-9.
  • 20. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365- 9.
  • 21. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973-8.
  • 22. Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893-9.
  • 23. Stephenson AJ, Wood DP, Kattan MW, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182:1357-63.
  • 24. O’Neil LM, Walsh S, Cohen RJ, Lee S. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence. BJU Int. 2015;116 (Suppl 3):42- 8.
  • 25. Stephenson AJ, Eggener SE, Hernandez AV, et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65:675-80.
  • 26. Alkhateeb S, Alibhai S, Fleshner N, et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010; 183:145.
  • 27. Yossepowitch O, Briganti A, Eastham JA, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014 Feb;65(2):303-13.
  • 28. Bolla M, Van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380:2018.
  • 29. Nishimura S, Ohashi T, Momma T, et al. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-doserate brachytherapy or external beam radiotherapy for localized prostate cancer. Cancer Med. 2018 May;7(5):1794-1801. doi: 10.1002/cam4.1443. Epub 2018 Mar 25. PMID: 29577651; PMCID: PMC5943430.
  • 30. Alcantara P, Hanlon A, Buyyounouski MK, et al. Prostatespecific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer. 2007 Jan 1;109(1):41-7. doi: 10.1002/cncr.22341. PMID: 17133416; PMCID: PMC1892752.
  • 31. Chung JH, Jeong JY, Lee JY, et al. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value. PLoS One. 2021 May 3;16(5):e0249709. doi: 10.1371/journal.pone.0249709. PMID: 33939714; PMCID: PMC8092790.
  • 32. Skove SL, Howard LE, Aronson WJ, et al. Timing of Prostatespecific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct;108:129-134. doi: 10.1016/j.urology.2017.07.009. Epub 2017 Jul 19. PMID: 28735016; PMCID: PMC6150912.
APA gökhan açıkgöz s, aral i, Öztürk H, aytac arslan s, Beyaz H, Altınışık İnan G, Tezcan Y (2022). Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. , 940 - 943. 10.5455/annalsmedres.2022.02.047
Chicago gökhan açıkgöz sedef,aral ipek pinar,Öztürk Hüseyin Furkan,aytac arslan suheyla,Beyaz Havva,Altınışık İnan Gonca,Tezcan Yilmaz Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. (2022): 940 - 943. 10.5455/annalsmedres.2022.02.047
MLA gökhan açıkgöz sedef,aral ipek pinar,Öztürk Hüseyin Furkan,aytac arslan suheyla,Beyaz Havva,Altınışık İnan Gonca,Tezcan Yilmaz Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. , 2022, ss.940 - 943. 10.5455/annalsmedres.2022.02.047
AMA gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. . 2022; 940 - 943. 10.5455/annalsmedres.2022.02.047
Vancouver gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. . 2022; 940 - 943. 10.5455/annalsmedres.2022.02.047
IEEE gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y "Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis." , ss.940 - 943, 2022. 10.5455/annalsmedres.2022.02.047
ISNAD gökhan açıkgöz, sedef vd. "Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis". (2022), 940-943. https://doi.org/10.5455/annalsmedres.2022.02.047
APA gökhan açıkgöz s, aral i, Öztürk H, aytac arslan s, Beyaz H, Altınışık İnan G, Tezcan Y (2022). Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. Annals of Medical Research, 29(9), 940 - 943. 10.5455/annalsmedres.2022.02.047
Chicago gökhan açıkgöz sedef,aral ipek pinar,Öztürk Hüseyin Furkan,aytac arslan suheyla,Beyaz Havva,Altınışık İnan Gonca,Tezcan Yilmaz Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. Annals of Medical Research 29, no.9 (2022): 940 - 943. 10.5455/annalsmedres.2022.02.047
MLA gökhan açıkgöz sedef,aral ipek pinar,Öztürk Hüseyin Furkan,aytac arslan suheyla,Beyaz Havva,Altınışık İnan Gonca,Tezcan Yilmaz Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. Annals of Medical Research, vol.29, no.9, 2022, ss.940 - 943. 10.5455/annalsmedres.2022.02.047
AMA gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. Annals of Medical Research. 2022; 29(9): 940 - 943. 10.5455/annalsmedres.2022.02.047
Vancouver gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis. Annals of Medical Research. 2022; 29(9): 940 - 943. 10.5455/annalsmedres.2022.02.047
IEEE gökhan açıkgöz s,aral i,Öztürk H,aytac arslan s,Beyaz H,Altınışık İnan G,Tezcan Y "Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis." Annals of Medical Research, 29, ss.940 - 943, 2022. 10.5455/annalsmedres.2022.02.047
ISNAD gökhan açıkgöz, sedef vd. "Factors affecting biochemical recurrence time in prostate cancer patients: A single center analysis". Annals of Medical Research 29/9 (2022), 940-943. https://doi.org/10.5455/annalsmedres.2022.02.047